Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XELOX + Sintilimab + Lenvatinib in AFP-positive Gastric Cancer
NCT06383559Phase 2Recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Dec 2023
- Primary completion
- Jul 2026
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of sintilimab, lenvatinib in gastric cancer (GC), sponsored by Tianjin Medical University Cancer Institute and Hospital. Started Dec 2023; status: recruiting.
02
Drugs
sintilimablenvatinib
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT06383559.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06383559.